Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse in Schizophrenia”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)Ended earlyNCT00946985
What this trial is testing

28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years

Who this might be right for
Schizophrenia
Ortho-McNeil Janssen Scientific Affairs, LLC 163
Post-approval studies (Phase 4)Study completedNCT00621777
What this trial is testing

Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder

Who this might be right for
SchizophreniaSchizoaffective DisorderBipolar Disorder+1 more
Massachusetts General Hospital 247
Not applicableStudy completedNCT00990626
What this trial is testing

Seroquel XR in Schizophrenia Relapse Prevention

Who this might be right for
Schizophrenia Relapse Prevention
AstraZeneca 1,600
Not applicableUnknownNCT00161408
What this trial is testing

Psychological Intervention for Relapse Prevention in First Episode Schizophrenia

Who this might be right for
Schizophrenic Disorders
University Hospital Tuebingen 106
Post-approval studies (Phase 4)Study completedNCT00320697
What this trial is testing

Smoking Relapse Prevention in Schizophrenia

Who this might be right for
SchizophreniaSchizoaffective DisorderSmokers
North Suffolk Mental Health Association 25
Large-scale testing (Phase 3)Study completedNCT00297388
What this trial is testing

How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder

Who this might be right for
SchizophreniaSchizoaffective Disorder
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 40
Not applicableStudy completedNCT02224430
What this trial is testing

Prediction of Relapse in Schizophrenia/Schizoaffective Disorder With Smartphones and On-body Sensors

Who this might be right for
SchizophreniaSchizoaffective Disorder
University of Alabama at Birmingham 40
Not applicableStudy completedNCT00399334
What this trial is testing

PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders

Who this might be right for
SchizophreniaSchizoaffective DisorderSchizophreniform Disorder
Janssen-Cilag, S.A. 1,607
Large-scale testing (Phase 3)Study completedNCT04959032
What this trial is testing

Lumateperone for the Prevention of Relapse in Patients With Schizophrenia

Who this might be right for
Schizophrenia
Intra-Cellular Therapies, Inc. 228
Not applicableStudy completedNCT02627716
What this trial is testing

Joint Crisis Plan Effectiveness in Preventing Relapses in Schizophrenia and Schizoaffective Disorder

Who this might be right for
Schizophrenia
University Hospital, Lille 124
Large-scale testing (Phase 3)Study completedNCT00283179
What this trial is testing

Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia

Who this might be right for
SchizophreniaSchizoaffective Disorder
Taiwan Otsuka Pharm. Co., Ltd 83
Not applicableLooking for participantsNCT06613334
What this trial is testing

Voice-Based Biomarkers: A Novel Approach to Monitoring and Predicting Schizophrenia Relapses

Who this might be right for
Schizophrenia
Centre Hospitalier St Anne 200
Post-approval studies (Phase 4)Study completedNCT02307396
What this trial is testing

Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

Who this might be right for
SchizophreniaSchizophrenia and Disorders With Psychotic FeaturesSchizoaffective Disorders
Technical University of Munich 21
Not applicableStudy completedNCT04060498
What this trial is testing

Mindfulness Intervention and Relapse in Psychosis

Who this might be right for
Psychosis
The University of Hong Kong 152
Post-approval studies (Phase 4)Study completedNCT00330863
What this trial is testing

Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy

Who this might be right for
SchizophreniaSchizoaffective Disorder
Northwell Health 357
Post-approval studies (Phase 4)Study completedNCT02360319
What this trial is testing

Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics

Who this might be right for
Schizophrenia
Vanguard Research Group 489
Not applicableUnknownNCT00192582
What this trial is testing

AIMHI NT Relapse Prevention Trial

Who this might be right for
SchizophreniaSchizoaffective DisorderPsychoses, Substance Induced+2 more
Menzies School of Health Research 90
Testing effectiveness (Phase 2)Ended earlyNCT03351244
What this trial is testing

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

Who this might be right for
Schizophrenia
Boehringer Ingelheim 264
Post-approval studies (Phase 4)UnknownNCT00220714
What this trial is testing

PREvent First Episode Relapse (PREFER)

Who this might be right for
Schizophrenia
State University of New York - Downstate Medical Center 80
Post-approval studies (Phase 4)Study completedNCT00299702
What this trial is testing

Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia

Who this might be right for
SchizophreniaPsychotic Disorders
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 355
Next Page